Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Geun Seog, Song"'
Autor:
Sungpil Han, Hee Youn Choi, Yo Han Kim, SeungChan Choi, Seokuee Kim, Ji Yeon Nam, Bongtae Kim, Geun Seog Song, Hyeong-Seok Lim, Kyun-Seop Bae
Publikováno v:
Gut and Liver, Vol 17, Iss 1, Pp 92-99 (2023)
Background/Aims: Tegoprazan, a novel potassium-competitive acid blocker, is expected to overcome the limitations of proton pump inhibitors and effectively control nocturnal acid breakthrough. To evaluate the pharmacodynamics of tegoprazan versus dexl
Externí odkaz:
https://doaj.org/article/031c5badeb3d4a6fa541965019b9a495
Autor:
Sejung Hwang, Jae-Wook Ko, Heechan Lee, Seokuee Kim, Bongtae Kim, Geun Seog Song, Jungryul Kim
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
Potassium-competitive acid blocker is a new class of drugs inhibiting gastric acid. It is controversial that vonoprazan showed the inhibitory activities of cytochrome P450 3A4. This study aimed to evaluate the pharmacokinetics (PK) of atorvastatin an
Externí odkaz:
https://doaj.org/article/0ac707387ef145729c9ab9d63d8e7a73
Autor:
Joon Sung Kim, Seung In Seo, Sun Hyung Kang, Sang Kil Lee, Ah Rong Kim, Hyun Wook Park, Bong Tae Kim, Geun Seog Song
Publikováno v:
Journal of Neurogastroenterology and Motility. 29:58-64
Autor:
Deok Yong Yoon, SeungHwan Lee, In-Jin Jang, Myeongjoong Kim, Heechan Lee, Seokuee Kim, Bongtae Kim, Geun Seog Song, Su-jin Rhee
Publikováno v:
Pharmaceutics, Vol 13, Iss 9, p 1489 (2021)
This study aimed to develop a physiologically based pharmacokinetic (PBPK) model of tegoprazan and to predict the drug–drug interaction (DDI) potential between tegoprazan and cytochrome P450 (CYP) 3A4 perpetrators. The PBPK model of tegoprazan was
Externí odkaz:
https://doaj.org/article/8aa6e5a4b6eb431b92e05edbac01cd09
Autor:
Eunsol Yang, Seokuee Kim, Bongtae Kim, Boram Kim, Yechan Kim, Sung Sup Park, Geun Seog Song, Kyung‐Sang Yu, In‐Jin Jang, SeungHwan Lee
Publikováno v:
British Journal of Clinical Pharmacology. 88:3288-3296
Nocturnal acid breakthrough has been considered an unmet need of proton-pump inhibitors. Tegoprazan, a novel potassium-competitive acid blocker, is expected to show improved properties for this unmet need. This study was aimed to compare night-time a
Autor:
Joon Seong Lee, Hyun Wook Park, Bong Tae Kim, Hoon Jai Chun, Eunji Kim, Dongho Lee, Kwang Hyun Ko, Sang Woo Lee, Joong Goo Kwon, Ah Rong Kim, Sang Gyun Kim, Hwoon-Yong Jung, Soo Heon Park, Kwang Bum Cho, Suck Chei Choi, Geun Seog Song, Yong Chan Lee, Hyojin Park, Sam Ryong Jee, Seun Ja Park, Seung Han Kim, Hyun Soo Kim, Jiwon Kim
Publikováno v:
Alimentary Pharmacology & Therapeutics
Summary Background Tegoprazan is a novel, fast‐ and long‐acting potassium‐competitive acid blocker that suppresses gastric acid secretion, which could benefit patients with non‐erosive reflux disease (NERD), a type of gastroesophageal reflux
Autor:
Minkyung Oh, Heechan Lee, Seokuee Kim, Bongtae Kim, Geun Seog Song, Jae-Gook Shin, Jong-Lyul Ghim
Publikováno v:
Translational & Clinical Pharmacology; Jun2023, Vol. 31 Issue 2, p114-123, 10p
Autor:
Joon Sung, Kim, Seung In, Seo, Sun Hyung, Kang, Sang Kil, Lee, Ah Rong, Kim, Hyun Wook, Park, Bong Tae, Kim, Geun Seog, Song
Publikováno v:
Journal of neurogastroenterology and motility.
Patients with gastroesophageal reflux disease (GERD) frequently experience nighttime heartburn and sleep disturbance. Tegoprazan is a new potassium-competitive acid blocker that can rapidly block acid secretion. This study aims to evaluate the effica
Autor:
Sungpil Han, Hee Youn Choi, Yo Han Kim, SeungChan Choi, Seokuee Kim, Ji Yeon Nam, Bongtae Kim, Geun Seog Song, Hyeong-Seok Lim, Kyun-Seop Bae
Publikováno v:
Gut and liver.
Tegoprazan, a novel potassium-competitive acid blocker, is expected to overcome the limitations of proton pump inhibitors and effectively control nocturnal acid breakthrough. To evaluate the pharmacodynamics of tegoprazan versus dexlansoprazole regar
Autor:
Su Jin Rhee, Geun Seog Song, Myeongjoong Kim, Heechan Lee, Seunghwan Lee, Seokuee Kim, In Jin Jang, Deok Yong Yoon, Bongtae Kim
Publikováno v:
Pharmaceutics, Vol 13, Iss 1489, p 1489 (2021)
Pharmaceutics
Volume 13
Issue 9
Pharmaceutics
Volume 13
Issue 9
This study aimed to develop a physiologically based pharmacokinetic (PBPK) model of tegoprazan and to predict the drug–drug interaction (DDI) potential between tegoprazan and cytochrome P450 (CYP) 3A4 perpetrators. The PBPK model of tegoprazan was